28 results about "Emtricitabine" patented technology

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a method for detecting related substances of an emtricitabine, propofol and tenofovir compound preparation. Specifically, the invention provides a high performance liquid chromatography detection method for the emtricitabine, propofol and tenofovir compound preparation related substances, and the method can realize rapid, simple and accurate separation and detection of the emtricitabine, propofol fumarate and tenofovir related substances. Therefore, the quality control requirements of the emtricitabine, propofol and tenofovir compound preparation are met.

The invention relates to the technical field of pharmaceutical analysis, and particularly discloses a high performance liquid chromatography-mass spectrometry tandem method (HPLC-MS / MS) for detecting a genotoxic impurity L-alanine isopropyl ester in an emtricitabine-propofol tenofovir tablet. By optimizing chromatographic column selection, a mobile phase gradient elution procedure and mass spectrometric detection parameters, the method realizes exclusive, sensitive and accurate detection of the L-isopropyl alanine. The methodological verification result shows that the detection limit is 1.00 ng / mL, the quantification limit is 2.00 ng / mL, the linear range is 2.00-100.00 ng / mL (the correlation coefficient r is equal to 0.9994), the recovery rate is stabilized between 92% and 98%, and the precision and repeatability are good. The detection method has the advantages of high sensitivity and strong selectivity, is suitable for quality control of emtricitabine propofol tenofovir tablets, meets the control requirements of ICH M7 guide on genotoxic impurities, and has good practicability and popularization value.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a detection method for related substances in a dotegravir-emtricitabine-propofol tenofovir compound preparation. The detection method comprises the following steps of: detecting the related substances in the compound preparation; specifically, the invention provides a high performance liquid chromatography detection method for related substances in a dotegravir-emtricitabine-propofol tenofovir compound preparation, and the method can realize rapid, simple and accurate separation and detection of related substances from dotegravir sodium, emtricitabine and propofol tenofovir fumarate. Therefore, the quality control requirements of the dotegravir-emtricitabine-propofol tenofovir compound preparation can be met.

The invention relates to the technical field of drug analysis and detection, and particularly discloses a method for detecting related substances in emtricitabine, propiophenol and tenofovir disoproxil fumarate tablets. According to the method, an octadecyl silane bonded silica gel chromatographic column is adopted, a mixed solution of a phosphate buffer solution and a tetrahydrofuran-acetonitrile solution in different volume ratios is taken as a mobile phase A and a mobile phase B respectively, and a gradient elution mode is adopted by a dual-wavelength high-performance liquid chromatography; the method can realize effective separation of a plurality of impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet, and accurately detect the condition of the impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet. The methodology research and verification of specificity, sensitivity and the like of the method provided by the invention find that the method provided by the invention is sensitive, accurate and relatively good in reproducibility, and accurate and quantitative detection of the related substances in the emtricitabine, propofol and tenofovir disoproxil tablet can be realized by using a simple, convenient and rapid method; and a reliable guarantee is provided for improving and better controlling the quality of the emtricitabine, propofol and tenofovir disoproxil fumarate tablet product.

The present invention provides a triple compound tablet and a preparation method thereof, the triple compound tablet comprises a first layer and a second layer, the first layer comprises 50-55 parts of bicrotegravir sodium with a particle size D90 of 10-200 [mu] m, 16-20 parts of polyvinyl alcohol, 220-240 parts of a filler, 20-30 parts of a disintegrating agent, and 2-8 parts of a lubricant; the second layer is prepared from 190 to 210 parts of emtricitabine, 25 to 30 parts of tenofovir alafenamide hemifumarate, 110 to 125 parts of a filling agent, 20 to 30 parts of a disintegrating agent and 2 to 8 parts of a lubricating agent. The bitegravir sodium is selected as an active component, the particle size of the bitegravir sodium is limited to meet the quality requirements of dissolution and tablet uniformity, adsorption of the bitegravir sodium can be reduced by selecting the specific disintegrating agent to improve the dissolution rate under the same condition, and the final drug effect is slightly influenced by the pH value of food, so that the bitegravir sodium tablet is convenient for patients to take.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a preparation method of a composite tablet. The preparation method comprises the following steps: S1, dissolving an adhesive and a wetting agent in water to form a solution; s2, putting the Aviavir, the lactose monohydrate, the filling agent and the disintegrating agent into a fluidized bed granulator, and introducing sterile hot air into the bottom of the fluidized bed granulator; spraying the solution of S1 into the top for wet granulation; s3, drying the wet particles in a fluidized bed to obtain dry particles; s4, uniformly mixing copibuxostat, colloidal silicon dioxide and a filling agent, crushing, sieving, and mixing with the crushed material in the step S3 and a lubricating agent to obtain a first material; s5, uniformly mixing emtricitabine, tenofovir propofol, the filler and the disintegrating agent, continuously and uniformly mixing with the lubricant, crushing and sieving; s6, mixing a disintegrating agent, a lubricating agent and the crushed material obtained in the step S52 to obtain a second material; and S7, performing double-layer tabletting on the first material and the second material. The composite tablet can improve the mixing uniformity of raw material medicines, and ensure the content uniformity and quality stability of medicines produced in different batches.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention provides a solid oral dosage form comprising tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, and emtricitabine, or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

1. Name of the design product: packaging box (metformin hydrochloride and pioglitazone hydrochloride tablet). 2. Use of the design product: the design product is used for the packaging of medicines. 3. Design points of the design product: the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt theroof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention discloses a method for synthesizing emtricitabine by Mitsunobu condensation, which belongs to the field of pharmaceutical chemistry technology. The key synthesis step is: (2R, 5R)-5-hydroxy-1,3-oxathiolane-2-carboxylic acid 1-menthyl ester (I) and N4-protected 5-fluorocytosine (II) are condensed by Mitusnobu reaction, followed by sodium borohydride reduction, and finally the protecting group is removed under acidic conditions to obtain emtricitabine. The method avoids the generation and separation of isomers, has short steps and high yield. The emtricitabine obtained by adopting the method has low cost, is easy to operate, and has mild reaction conditions, which shows the superiority and simplicity of the synthetic method.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

1. Name of the product of this design: Pharmaceutical packaging box (Emtricitabine and Tenofovir Tablets Series). 2. Purpose of this design product: This design product is used for packaging of medicines. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the key points of the design: Main view of Design 1. 5. Designate Design 1 as the base design.

Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developing an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, wherein the one or more therapeutic(s) is or comprise rifabutin, one or more nucleoside analog reverse transcriptase inhibitor(s), optionally selected from lamivudine, emtricitabine, tenofovir disoproxil funiarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, and / or stavudine, losartan, or a combination thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The application discloses a preparation method of an intermediate of entecavir, and the intermediate is prepared from dimethyl oxalate through four steps of amidation, ring closure, reduction and chlorination to obtain 3-(chloromethyl)-1-methyl-1 H -1,2,4-triazole hydrochloride with high purity. The application has the advantages of mild reaction condition, simple operation, high yield, low cost and suitability for industrial production.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention relates to a method for simultaneously detecting the concentration of bicotegravir and emtricitabine in human plasma. The detection method comprises the following steps: pretreating a sample to be detected by an acetonitrile protein precipitation method, analyzing chromatographic column separation, and then detecting by an ultraviolet detector. The method has the advantages of less sample sampling, simple pretreatment, no need of expensive equipment and reagents, low cost, and simple and economical analysis and monitoring of the bitovin concentration change during AIDS treatment.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention is relates to an identification and isolation of an emtricitabine degradation impurity compounds. The present invention also relates to process of preparing the emtricitabine impurity compounds by photocatalytic forced degradation study.